U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H7NO.C4H6O6
Molecular Weight 259.2127
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NICOTINYL ALCOHOL TARTRATE

SMILES

OCC1=CN=CC=C1.O[C@H]([C@@H](O)C(O)=O)C(O)=O

InChI

InChIKey=NPORIZAYKBQYLF-LREBCSMRSA-N
InChI=1S/C6H7NO.C4H6O6/c8-5-6-2-1-3-7-4-6;5-1(3(7)8)2(6)4(9)10/h1-4,8H,5H2;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1

HIDE SMILES / InChI

Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C6H7NO
Molecular Weight 109.1259
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Nicotinyl alcohol is a direct-acting vasolidator, that may decrease the blood pressure and it is a cholesterol-lowering agent. Nicotinyl alcohol as a tartrate salt led to the efficiency improvements in patients with intermittent claudication. In addition, nicotinyl alcohol alone or associated with other drugs was studied in the treatment of radicular syndromes; and was shown, that the effect had not been due to mechanical compression.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ronicol

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 30 - 66 years
n = 20
Health Status: unhealthy
Condition: hyperlipoproteinemia
Age Group: 30 - 66 years
Sex: M+F
Population Size: 20
Sources:
Other AEs: Increased appetite, Skin rash...
Other AEs:
Increased appetite (15%)
Skin rash (36%)
Itching (37%)
Flushing (68%)
Nausea (50%)
Abdominal pain (15%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 15%
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 30 - 66 years
n = 20
Health Status: unhealthy
Condition: hyperlipoproteinemia
Age Group: 30 - 66 years
Sex: M+F
Population Size: 20
Sources:
Increased appetite 15%
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 30 - 66 years
n = 20
Health Status: unhealthy
Condition: hyperlipoproteinemia
Age Group: 30 - 66 years
Sex: M+F
Population Size: 20
Sources:
Skin rash 36%
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 30 - 66 years
n = 20
Health Status: unhealthy
Condition: hyperlipoproteinemia
Age Group: 30 - 66 years
Sex: M+F
Population Size: 20
Sources:
Itching 37%
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 30 - 66 years
n = 20
Health Status: unhealthy
Condition: hyperlipoproteinemia
Age Group: 30 - 66 years
Sex: M+F
Population Size: 20
Sources:
Nausea 50%
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 30 - 66 years
n = 20
Health Status: unhealthy
Condition: hyperlipoproteinemia
Age Group: 30 - 66 years
Sex: M+F
Population Size: 20
Sources:
Flushing 68%
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 30 - 66 years
n = 20
Health Status: unhealthy
Condition: hyperlipoproteinemia
Age Group: 30 - 66 years
Sex: M+F
Population Size: 20
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischemic injury during norepinephrine infusion in dogs.
1974 May
Metabolism of myosmine in Wistar rats.
2005 Nov
Reaction of the tobacco alkaloid myosmine with hydrogen peroxide.
2006 Jan
Picolinyl ester fragmentation mechanism studies with application to the identification of acylcarnitine acyl groups following transesterification.
2006 Nov
Enzymatic oxidation of NADP+ to its 4-oxo derivative is a side-reaction displayed only by the adrenodoxin reductase type of ferredoxin-NADP+ reductases.
2007 Aug
catena-Poly[[tetrakis(mu-propionato-kappa(2)O:O')dicopper(II)]-mu-3-pyridylmethanol-kappa(2)N:O-[bis(propionato-kappaO)bis(3-pyridylmethanol-kappaN)copper(II)]-mu-3-pyridylmethanol-kappaO:N].
2007 Mar
catena-Poly[[bis-[2-(2,3-dimethyl-anilino)benzoato-κO]cadmium(II)]-di-μ-3-pyridylmethanol-κN:O;κO:N].
2008 Feb 6
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
2008 Mar 15
Equilibria of 3-pyridylmethanol with copper(II). A comparative electron spin resonance study by the decomposition of spectra in liquid and frozen solutions.
2008 Oct 16
Characterization of a rat NADPH-dependent aldo-keto reductase (AKR1B13) induced by oxidative stress.
2009 Mar 16
Development of molecularly imprinted polymers as tailored templates for the solid-state [2+2] photodimerization.
2009 Nov 15
A rapid and sensitive method for the simultaneous analysis of aliphatic and polar molecules containing free carboxyl groups in plant extracts by LC-MS/MS.
2009 Nov 25
Oxidation of alcohols using a manganese (II) complex based on a pentakis benzimidazole amide ligand.
2009 Oct 1
Synthesis and Structural Characterization of a Metal Cluster and a Coordination Polymer Based on the [Mn(6)(mu(4)-O)(2)] Unit.
2010
The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine.
2010 Jan
Noncovalent synthesis of hierarchical zinc phosphates from a single Zn(4)O(12)P(4) double-four-ring building block: dimensionality control through the choice of auxiliary ligands.
2010 Jan 18
Copper (II) complexes of the anti-inflammatory drug naproxen and 3-pyridylmethanol as auxiliary ligand. Characterization, superoxide dismutase and catecholase--mimetic activities.
2010 Sep
Patents

Sample Use Guides

25 mg tablet 4 times a daily
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:26:18 GMT 2023
Edited
by admin
on Fri Dec 15 15:26:18 GMT 2023
Record UNII
5G605ZIE90
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NICOTINYL ALCOHOL TARTRATE
JAN   MART.   VANDF  
Systematic Name English
NICOTINYL TARTRATE
INCI   WHO-DD  
INCI  
Official Name English
3-(HYDROXYMETHYL)PYRIDINE TARTRATE
Systematic Name English
NSC-147492
Code English
NICOTINYL TARTRATE [INCI]
Common Name English
NICOTINYL ALCOHOL D-TARTRATE [MI]
Common Name English
3-PYRIDINEMETHANOL, (R-(R*,R*))-2,3-DIHYDROXYBUTANEDIOATE (1:1) (SALT)
Common Name English
3-PYRIDYLMETHANOL-(RR)-HYDROGENTARTRATE
Common Name English
NICOTINYL ALCOHOL TARTRATE [MART.]
Common Name English
NICOTINYL ALCOHOL TARTRATE [VANDF]
Common Name English
3-PYRIDINEMETHANOL TARTRATE (1:1) SALT
Common Name English
NICOTINYL ALCOHOL D-TARTRATE
MI  
Systematic Name English
Nicotinyl tartrate [WHO-DD]
Common Name English
NICOTINYL ALCOHOL TARTRATE [JAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29707
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
Code System Code Type Description
RXCUI
235354
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
PRIMARY RxNorm
NSC
147492
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
PRIMARY
MERCK INDEX
m7882
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
PRIMARY Merck Index
FDA UNII
5G605ZIE90
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
PRIMARY
EVMPD
SUB14652MIG
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
PRIMARY
ECHA (EC/EINECS)
228-199-1
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
PRIMARY
EPA CompTox
DTXSID90977232
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
PRIMARY
NCI_THESAURUS
C77152
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
PRIMARY
SMS_ID
100000079995
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
PRIMARY
PUBCHEM
93578
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
PRIMARY
CAS
6164-87-0
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
PRIMARY
ChEMBL
CHEMBL1235535
Created by admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY